Related Experiment Videos

[Polyresistant Streptococcus pneumoniae causing cumulative diseases in infants and young children]

I Marosvári1, Z Nagy, I Budai

  • 1Fövárosi Szent János Kórház, Budapest.

Orvosi Hetilap
|June 27, 1993
PubMed

Insights

Penicillin-resistant Streptococcus pneumoniae strains showed resistance to multiple antibiotics, including cephalosporines. However, third-generation cephalosporines like Cefotaxime effectively treated these infections, leading to patient recovery.

Area of Science:

  • Microbiology
  • Infectious Diseases
  • Pharmacology

Background:

  • Streptococcus pneumoniae is a leading cause of bacterial infections.
  • Antibiotic resistance in S. pneumoniae poses a significant public health threat.
  • Emergence of multidrug-resistant strains necessitates evaluation of alternative treatment options.

Observation:

  • Eight cases of S. pneumoniae infections are presented.
  • Isolated strains exhibited resistance to Penicillin, Oxacillin, Erythromycin, Ampicillin, and Cotrimoxazole.
  • Five strains also demonstrated resistance to second-generation cephalosporines (Cefaclor, Cefuroxime).

Findings:

  • All multidrug-resistant S. pneumoniae strains remained susceptible to third-generation cephalosporines (Cefotaxime, Ceftriaxone).
  • Treatment with Cefotaxime (Claforan) led to complete recovery in all reported patients.
  • This highlights the continued efficacy of third-generation cephalosporines against resistant S. pneumoniae.

Implications:

  • Third-generation cephalosporines are a viable therapeutic option for infections caused by multidrug-resistant S. pneumoniae.
  • Continued surveillance of antibiotic resistance patterns is crucial for guiding clinical practice.
  • These findings support the use of Cefotaxime in treating severe S. pneumoniae infections with documented resistance to other agents.

Related Concept Videos